LEADER 03105nam  2200613Ia 450 
001 9910438027003321
005 20200520144314.0
010   $a1-299-33548-9
010   $a1-4614-5851-X
024 7 $a10.1007/978-1-4614-5851-7
035   $a(CKB)2670000000326567
035   $a(EBL)1082016
035   $a(OCoLC)827212489
035   $a(SSID)ssj0000879385
035   $a(PQKBManifestationID)11487981
035   $a(PQKBTitleCode)TC0000879385
035   $a(PQKBWorkID)10852956
035   $a(PQKB)11582977
035   $a(DE-He213)978-1-4614-5851-7
035   $a(MiAaPQ)EBC1082016
035   $a(PPN)168304066
035   $a(EXLCZ)992670000000326567
100   $a20130212d2013      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aNon-hodgkin lymphoma $eprognostic factors and targets /$fPeter J. Quesenberry, Jorge J. Castillo, editors
205   $a1st ed. 2013.
210   $aNew York, NY $cHumana Press$dc2013
215   $a1 online resource (299 p.)
225  0$aCancer drug discovery and development
300   $aDescription based upon print version of record.
311   $a1-4899-9419-X 
311   $a1-4614-5850-1 
320   $aIncludes bibliographical references and index.
327   $aCancer Stem Cells: A Matter of Perspective -- B and T-cell development -- HIV lymphomagenesis -- Epstein-Barr Virus Lymphomagenesis and Therapeutic Targets -- Antigen driven lymphomagenesis -- Pre-clinical lymphoma models -- Prognostic factors in B-cell lymphoma -- Prognostic factors in T-cell lymphoma -- Prognostic factors in HIV-associated lymphoma -- Future directions on the treatment of aggressive non-Hodgkin lymphoma -- New monoclonal antibodies for indolent non-Hodgkin lymphomas -- Current therapies for T-cell lymphoma -- Stem Cell Transplantation for lymphoma -- Autologous stem cell transplantation in non-Hodgkin lymphoma -- The role of Stem Cell Transplantation for HIV-associated lymphoma -- Stem Cell Transplantation for T-cell lymphoma -- Index.
330   $aRecent developments in the therapy of non-Hodgkin lymphoma have improved response and survival rates in patients with these conditions. This book is focused on the biology, prognostic factors and novel targets of non-Hodgkin lymphoma. We believe that understanding the pathophysiology of non-Hodgkin lymphoma provides a mean to improve its risk-stratification and treatment. This book is intended for medical and healthcare professionals involved in the research and clinical care of patients with non-Hodgkin lymphoma.
410  0$aCancer Drug Discovery and Development,$x2196-9906
606   $aLymphomas$xRisk factors
606   $aLymphomas
615  0$aLymphomas$xRisk factors.
615  0$aLymphomas.
676   $a616.994460724
701   $aCastillo$b Jorge J$01754812
701   $aQuesenberry$b Peter J$01754813
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910438027003321
996   $aNon-hodgkin lymphoma$94191309
997   $aUNINA